Moneycontrol PRO

Buy Ipca Laboratories: target of Rs 2850: Sharekhan

Sharekhan is bullish on Ipca Laboratories has recommended buy rating on the stock with a target price of Rs 2850 in its research report dated September 09, 2021.

September 13, 2021 / 02:48 PM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Ipca Laboratories

IPCA laboratories (IPCA) domestic formulations business is on a strong footing and is expected to be a key growth driver with a likely double digit growth for FY22. IPCA’s presence in the fast growing therapies coupled with positive rub off effect of a strong IPM growth could be the key drivers for domestic formulations business. For the API segment, completion of Dewas greenfield (expected to add 25% of capacities) by FY2023 and a strong demand outlook would be the key drivers. At CMP the stock trades at 27.2x /24.1x its FY22E and FY23E EPS. Strong earnings prospects, a sturdy balance sheet, and healthy return ratios augur well for IPCA.


We maintain Buy recommendation with a revised PT of Rs 2850.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Sep 13, 2021 02:48 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark